IDH1 and glioblastoma: In the first and second clusters, patients with IDH wild-type GBM and elevated Ki-67 expression had increased levels of EV markers associated with poor prognosis, EMT transition, cell proliferation, stemness, neoangiogenesis, and therapy resistance.